$6.750
-0.413 (-6.12%)At close
ATHA News
ATHA Events
Athira Pharma Files to Sell 58.46M Shares of Common Stock
Athira Pharma files to sell 58.46M shares of common stock for holders
Athira Pharma Renames to LeonaBio, Changes Ticker to LONA
Athira Pharma has changed its name to LeonaBio, Inc. The name change aligns with the Company's transformative acquisition of rights to develop and commercialize lasofoxifene, a promising late-stage clinical asset for the potential treatment of metastatic breast cancer, currently in a Phase 3 trial. In connection with the name change, the Company will change its ticker symbol to "LONA." The Company's common stock will commence trading on The Nasdaq Capital Market under the new ticker symbol on January 12, 2026. "This marks an exciting and transformative period for our company and emphasizes our commitment to advancing a pipeline of innovative, late-stage assets both internally developed and strategically in-licensed with the goal of accelerating their path to market and maximizing their potential clinical and commercial impact," said Mark Litton, CEO. "At LeonaBio, we are building a pipeline with the potential to change lives and create enduring value. Our new name truly reflects our commitment to leadership, resilience, and innovation-qualities that define our expanded mission to deliver transformative therapies for patients battling diseases that need better treatment options."
Athira Pharma Acquires Rights for Lasofoxifene Development and Secures $90 Million Financing
Athira Pharma announced that it has entered into an agreement to acquire the rights for the development and commercialization of lasofoxifene, a clinical asset in a potentially registrational Phase 3 trial. The ongoing Phase 3 ELAINE-3 clinical trial is greater than 50% enrolled with data expected in mid-2027. Athira has acquired an exclusive global license from Sermonix Pharmaceuticals, Inc. for rights to develop and commercialize lasofoxifene, a selective estrogen receptor modulator for the potential treatment of metastatic breast cancer. In conjunction with this transaction, Athira also announced an upfront financing of $90 million in private placement financing of common stock and warrants, with the warrants providing, if exercised, up to an additional $146 million to support development of the new program through key clinical and regulatory milestones. The financing was co-led by Commodore Capital, Perceptive Advisors, and TCGX, with participation from ADAR1, Blackstone Multi-Asset Investing, Kalehua Capital, Ligand Pharmaceuticals, New Enterprise Associates, Spruce Street Capital, and 9vc. The Company anticipates the upfront financing will support lasofoxifene development through its topline data readout and key regulatory milestones, with sufficient capital for runway into 2028.
Athira Pharma declares a 10-for-1 reverse stock split.
Athira Pharma announced that it will effect a 10-for-1 reverse stock split of Athira's issued and authorized common stock. Athira's stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company's Annual Meeting of Stockholders held on May 29, 2025.
Athira Pharma presents results from Phase 1 trial of ATH-1105 at ALS Nexus
Athira Pharma presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in Dallas, Texas. ALS Nexus convenes leading experts from the ALS community, including researchers, healthcare professionals, advocates and individuals living with amyotrophic lateral sclerosis, ALS, to connect and learn about advances in research, clinical care and advocacy. ATH-1105 is the Company's novel, orally available, CNS-penetrant, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including ALS. Results from the Phase 1 trial of ATH-1105 demonstrated a favorable safety and tolerability profile as well as dose-proportional pharmacokinetics and CNS penetration. ATH-1105 has also demonstrated consistent and robust beneficial effects in preclinical models of ALS.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.